No Data
No Data
Haizheng Pharmaceutical (600267.SH): Completed the repurchase and actually repurchased 0.97% of the company's shares
Gelonghui, April 19, 丨 Haizheng Pharmaceutical (600267.SH) announced that on April 18, 2024, the company's third share repurchase plan was completed. It actually repurchased 11.6872 million shares, accounting for 0.97% of the company's total share capital. The highest repurchase price was 9.75 yuan/share, the lowest repurchase price was 7.17 yuan/share, the average repurchase price was 8.47 yuan/share, and the total capital used was 98.99.27 million yuan (excluding transaction fees).
Hisun Pharma's Unit Gets Nod for Pig Vaccine
Zhejiang Hisun Pharmaceutical's (SHA:600267) unit, Yunnan Biopharmaceutical, received approval for a pig vaccine from China's Ministry of Agriculture and Rural Affairs, the pharmaceutical company said
Haizheng Pharmaceutical: No downward revisions to the “Haizheng Dingzheng Transfer” share conversion price
Zhejiang Haizheng Pharmaceutical Co., Ltd. announced that as of April 15, 2024, the company will trigger a downward revision of the “Haizheng Transfer” share conversion price. After deliberation and approval at the 26th meeting of the 9th board of directors of the company, the board of directors of the company decided not to exercise the right to revise the “Haizheng Transfer” share conversion price downward, and that within the next 12 months (April 16, 2024 to April 15, 2025), if once again triggering the terms of downward revision of the conversion price of convertible corporate bonds (hereinafter referred to as “convertible bonds”), it will not propose a downward correction plan.
Haizheng Pharmaceutical (600267.SH): It has repurchased a total of 7.829,900 shares at a cost of 697.16,300 yuan
Gelonghui, April 1, 丨 Haizheng Pharmaceutical (600267.SH) announced that as of March 31, 2024, the company had repurchased a total of 7.829,900 shares, accounting for 0.6482% of the company's total share capital. The highest purchase price was 9.75 yuan/share, the lowest price was 7.17 yuan/share, and the total amount paid was 697.16,300 yuan (excluding transaction fees).
Further Weakness as Zhejiang Hisun Pharmaceutical (SHSE:600267) Drops 5.0% This Week, Taking Three-year Losses to 46%
Many investors define successful investing as beating the market average over the long term. But its virtually certain that sometimes you will buy stocks that fall short of the market average returns
Zhitong A Share Sale Restriction and Release List | March 25
According to the Zhitong Finance App, the ban on restricted shares of 18 listed companies was lifted on March 25, with a total market value of about 23.024 billion yuan. Today's specific sales restrictions and unbanned shares are as follows: Stock abbreviation, stock code, restricted share type, number of unbanned shares Zotye Auto 000980 additional A shares, corporate placement, listing 471 million, Haizheng Pharmaceutical 600267, corporate placement, listing 599315 Wan Aixu shares 600732 share incentives limited sale and circulation 3308 million Ruifeng Bank 601,528 shares restricted circulation before issuance, 9897 thousand Muyuan shares 002714 share incentives limited sale and circulation 2515
No Data